Ulipristal acetate 5mg prescribing for uterine fibroids by all Sub-ICB Locations

Why it matters: The MHRA has a clear safety direction advising that patients taking Esmya (ulipristal acetate) for uterine fibroids should STOP their treatment IMMEDIATELY.

Any prescribing on this measure should prompt investigation to identify patients and ensure the treatment is stopped and followup blood tests arranged.

Please note that this is an experimental measure to support a new type of alert. We would be grateful for any feedback at [email protected].

Description: Number of items for ulipristal acetate 5mg per 1000 patients

Explore:

• View this measure on the analyse page.
• View technical details for this measure.

Tagged as: Safety, Reproductive system (or browse all measures)

Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.

View measure for NHS England combined →

---

Fetching data...